

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/223740 A1

(51) International Patent Classification:

A61K 31/4188 (2006.01) A61P 17/06 (2006.01)
A61K 31/506 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2024/061394

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

25 April 2024 (25.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23315116.6 26 April 2023 (26.04.2023) EP
63/539,764 21 September 2023 (21.09.2023) US

(71) Applicant: **SANOFI** [FR/FR]; 46 avenue de la Grande Armée, 75017 Paris (FR).

(72) Inventors: **CHOW, Ohn**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **NASSR, Nassr**; c/o Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, 65926 Frankfurt (DE). **NGUYEN, Mai Anh**; c/o Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, 65926 Frankfurt (DE). **PERRIN, Laurent**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

(74) Agent: **MATHYS & SQUIRE**; The Shard, 32 London Bridge Street, London Greater London SE1 9SG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATING PSORIASIS USING A SMALL MOLECULE INHIBITOR OF TUMOR NECROSIS FACTOR ALPHA

(57) Abstract: Provided herein are treatments for psoriasis, wherein a human subject is administered a 400 mg daily dose of Compound 1 or a pharmaceutically acceptable salt thereof.

WO 2024/223740 A1